Switch theme
Sign up to access all valuation multiples
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
2015
627
LTM Revenue $204M
LTM EBITDA -$361M
$8.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Arcus Biosciences has a last 12-month revenue (LTM) of $204M and a last 12-month EBITDA of -$361M.
In the most recent fiscal year, Arcus Biosciences achieved revenue of $258M and an EBITDA of -$269M.
Arcus Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Arcus Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $204M | XXX | $258M | XXX | XXX | XXX |
| Gross Profit | $204M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$361M | XXX | -$269M | XXX | XXX | XXX |
| EBITDA Margin | -177% | XXX | -104% | XXX | XXX | XXX |
| EBIT | -$391M | XXX | -$310M | XXX | XXX | XXX |
| EBIT Margin | -192% | XXX | -120% | XXX | XXX | XXX |
| Net Profit | -$355M | XXX | -$283M | XXX | XXX | XXX |
| Net Margin | -174% | XXX | -110% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Arcus Biosciences's stock price is $9.
Arcus Biosciences has current market cap of $946M, and EV of $8.6M.
See Arcus Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.6M | $946M | XXX | XXX | XXX | XXX | $-3.72 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Arcus Biosciences has market cap of $946M and EV of $8.6M.
Arcus Biosciences's trades at 0.0x EV/Revenue multiple, and -0.0x EV/EBITDA.
Equity research analysts estimate Arcus Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arcus Biosciences has a P/E ratio of -2.7x.
See valuation multiples for Arcus Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $946M | XXX | $946M | XXX | XXX | XXX |
| EV (current) | $8.6M | XXX | $8.6M | XXX | XXX | XXX |
| EV/Revenue | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
| EV/EBITDA | -0.0x | XXX | -0.0x | XXX | XXX | XXX |
| EV/EBIT | -0.0x | XXX | -0.0x | XXX | XXX | XXX |
| EV/Gross Profit | 0.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.7x | XXX | -3.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialArcus Biosciences's last 12 month revenue growth is -29%
Arcus Biosciences's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.9M for the same period.
Arcus Biosciences's rule of 40 is -278% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Arcus Biosciences's rule of X is -250% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Arcus Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -29% | XXX | -19% | XXX | XXX | XXX |
| EBITDA Margin | -177% | XXX | -104% | XXX | XXX | XXX |
| EBITDA Growth | 29% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -278% | XXX | -133% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -250% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 174% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 220% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arcus Biosciences acquired XXX companies to date.
Last acquisition by Arcus Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Arcus Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Arcus Biosciences founded? | Arcus Biosciences was founded in 2015. |
| Where is Arcus Biosciences headquartered? | Arcus Biosciences is headquartered in United States of America. |
| How many employees does Arcus Biosciences have? | As of today, Arcus Biosciences has 627 employees. |
| Who is the CEO of Arcus Biosciences? | Arcus Biosciences's CEO is Dr. Terry Rosen, PhD. |
| Is Arcus Biosciences publicy listed? | Yes, Arcus Biosciences is a public company listed on NYS. |
| What is the stock symbol of Arcus Biosciences? | Arcus Biosciences trades under RCUS ticker. |
| When did Arcus Biosciences go public? | Arcus Biosciences went public in 2018. |
| Who are competitors of Arcus Biosciences? | Similar companies to Arcus Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Arcus Biosciences? | Arcus Biosciences's current market cap is $946M |
| What is the current revenue of Arcus Biosciences? | Arcus Biosciences's last 12 months revenue is $204M. |
| What is the current revenue growth of Arcus Biosciences? | Arcus Biosciences revenue growth (NTM/LTM) is -29%. |
| What is the current EV/Revenue multiple of Arcus Biosciences? | Current revenue multiple of Arcus Biosciences is 0.0x. |
| Is Arcus Biosciences profitable? | Yes, Arcus Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Arcus Biosciences? | Arcus Biosciences's last 12 months EBITDA is -$361M. |
| What is Arcus Biosciences's EBITDA margin? | Arcus Biosciences's last 12 months EBITDA margin is -177%. |
| What is the current EV/EBITDA multiple of Arcus Biosciences? | Current EBITDA multiple of Arcus Biosciences is -0.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
